- Home
- DBI vs LXRX Comparison
DBI vs LXRX Comparison
Compare DBI & LXRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DBI
- LXRX
- Stock Information
- Founded
- DBI 1991
- LXRX 1995
- Country
- DBI United States
- LXRX United States
- Employees
- DBI N/A
- LXRX N/A
- Industry
- DBI Clothing/Shoe/Accessory Stores
- LXRX Biotechnology: Pharmaceutical Preparations
- Sector
- DBI Consumer Discretionary
- LXRX Health Care
- Exchange
- DBI Nasdaq
- LXRX Nasdaq
- Market Cap
- DBI 137.2M
- LXRX 124.4M
- IPO Year
- DBI 1991
- LXRX 2000
- Fundamental
- Price
- DBI $3.30
- LXRX $0.70
- Analyst Decision
- DBI Hold
- LXRX Buy
- Analyst Count
- DBI 2
- LXRX 4
- Target Price
- DBI $4.75
- LXRX $3.67
- AVG Volume (30 Days)
- DBI 1.5M
- LXRX 5.7M
- Earning Date
- DBI 06-03-2025
- LXRX 05-13-2025
- Dividend Yield
- DBI 6.07%
- LXRX N/A
- EPS Growth
- DBI N/A
- LXRX N/A
- EPS
- DBI N/A
- LXRX N/A
- Revenue
- DBI $3,009,262,000.00
- LXRX $31,081,000.00
- Revenue This Year
- DBI $2.22
- LXRX N/A
- Revenue Next Year
- DBI $2.18
- LXRX $84.78
- P/E Ratio
- DBI N/A
- LXRX N/A
- Revenue Growth
- DBI N/A
- LXRX 2481.48
- 52 Week Low
- DBI $2.44
- LXRX $0.28
- 52 Week High
- DBI $11.06
- LXRX $2.45
- Technical
- Relative Strength Index (RSI)
- DBI 57.04
- LXRX 60.07
- Support Level
- DBI $2.78
- LXRX $0.63
- Resistance Level
- DBI $3.38
- LXRX $0.71
- Average True Range (ATR)
- DBI 0.17
- LXRX 0.07
- MACD
- DBI 0.11
- LXRX -0.00
- Stochastic Oscillator
- DBI 90.00
- LXRX 55.00
About DBI Designer Brands Inc.
Designer Brands Inc is a designer, producer, and retailer of footwear and accessories. The company operates in three reportable segments: the U.S. Retail segment, the Canada Retail segment and the Brand Portfolio segment. The U.S. Retail segment operates the DSW Designer Shoe Warehouse banner through its direct-to-consumer U.S. stores and e-commerce site. The Canada Retail segment operates The Shoe Company and DSW banners through its direct-to-consumer Canada stores and e-commerce sites. The Brand Portfolio segment earns revenue from the sale of wholesale products to retailers, commissions for serving retailers as the design and buying agent for products under private labels, and the sale of branded products through its direct-to-consumer e-commerce sites.
About LXRX Lexicon Pharmaceuticals Inc.
Lexicon Pharmaceuticals Inc is a biopharmaceutical company. It is engaged in the discovery, development, and commercialization of pharmaceutical products for the treatment of human diseases. Some of its drug candidates are LX9211, an orally-delivered small molecule drug candidate, as a treatment for neuropathic pain; and sotagliflozin, an orally-delivered small molecule drug candidate, as a treatment for heart failure and type 1 diabetes.